Flying solo for a change, Sanofi says isatuximab scored an important success in first PhIII myeloma study
Maybe Sanofi can develop a major new oncology drug on its own.
Early Tuesday the pharma giant announced the successful — topline — Phase III outcome for isatuximab, its anti-CD38 treatment for multiple myeloma. Researchers said the drug hit the endpoint on progression-free survival among patients who had been treated with at least two earlier therapies.
There’s no data yet, but it will be closely watched when Sanofi does post the results as it hustles a new drug application to regulators.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
